cts, with a focus on pharmaceutical products
for the treatment of diseases and consumer products for the maintenance of
everyday health. Otsuka is committed to being a corporation that creates
global value, adhering to the high ethical standards required of a company
involved in human health and life, maintaining a dynamic corporate culture,
and working in harmony with local communities and the natural environment.
The Otsuka Pharmaceutical Group comprises 99 companies and employs
approximately 31,000 people in 17 countries and regions worldwide. Otsuka
and its consolidated subsidiaries earned U.S. $7.2 billion in annual
revenues in fiscal 2006.
Bristol-Myers Squibb is a global pharmaceutical and related healthcare
products company whose mission is to extend and enhance human life.
For more information and FULL PRESCRIBING INFORMATION,
including Boxed WARNING, visit: http://www.abilify.com
Visit Bristol-Myers Squibb at: http://www.bms.com
Visit Otsuka Pharmaceutical Co., Ltd. at: http://www.otsuka-global.com
* Inadequate response for prospective treatment was defined as less than
50 percent improvement on the 17-item version of the Hamilton Depression
Rating Scale (HAMD17), minimal HAMD17 score of 14, and a Clinical Global
Impressions Improvement rating of no better than minimal improvement.
(1) Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer-Term
Outcomes in Depressed Outpatients Requiring One or Several Treatment
Steps: A STAR*D Report. Am J Psych. 2006;163:1905-1917.
(2) Kessler RC, Berglund P, Demler O, et al. The epidemiology of major
depressive disorder: results from the national comorbidity survey
replication (NCS-R). JAMA. June 18 2003;289(23):3095-3105.
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.|
Copyright©2007 PR Newswire.
All rights reserved
. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology2
. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List3
. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved4
. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir5
. Korean Food and Drug Administration Approval for ActiPatch Achieved6
. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait7
. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania8
. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox9
. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program10
. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia11
. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)